Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Research & Development (2016 - 2025)

Ironwood Pharmaceuticals' Research & Development history spans 16 years, with the latest figure at $21.9 million for Q4 2025.

  • For Q4 2025, Research & Development fell 13.89% year-over-year to $21.9 million; the TTM value through Dec 2025 reached $95.1 million, down 14.62%, while the annual FY2025 figure was $95.1 million, 14.62% down from the prior year.
  • Research & Development for Q4 2025 was $21.9 million at Ironwood Pharmaceuticals, down from $22.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $35.7 million in Q4 2023 and bottomed at $6.0 million in Q2 2023.
  • The 5-year median for Research & Development is $22.2 million (2025), against an average of $20.4 million.
  • The largest annual shift saw Research & Development plummeted 67.2% in 2022 before it skyrocketed 406.47% in 2024.
  • A 5-year view of Research & Development shows it stood at $31.9 million in 2021, then plummeted by 67.2% to $10.4 million in 2022, then surged by 241.53% to $35.7 million in 2023, then fell by 28.83% to $25.4 million in 2024, then fell by 13.89% to $21.9 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Research & Development are $21.9 million (Q4 2025), $22.5 million (Q3 2025), and $23.4 million (Q2 2025).